HALPHABAROL THERAPY IN EGYPTIAN PATIENTS WITH CIRRHOSIS AND DIURETIC-RESISTANT ASCITES
Journal Title: European Journal of Biomedical and Pharmaceutical Sciences - Year 2017, Vol 4, Issue 5
Abstract
Background: Liver cirrhosis accounts for over 75% of all episodes of ascites. One of the most serious complications in cirrhotic patients with ascites is the occurrence of refractoriness that is the inability to resolve ascites by the standard diuretic therapy. Diuretic–resistant ascites is defined as failure to respond to maximal tolerated doses of spironolactone and frusemide. At this point, the need for serial therapeutic paracentesis (abdominal tapping) becomes a must. Objectives: The aim of this study is to evaluate the diuretic effects of halphabarol and its possible role in the mobilization and control of ascites in cirrhotic ascitic patients resistant to maximal tolerated doses of standard diuretic therapy (SDT). Patients and methods: A total of 44 cirrhotic patients with diuretic-resistant ascites were prospectively studied after 1 month administration of SDT alone (n = 22) or in combination with halphabarol (n = 23) in a randomized controlled open-label pilot study. Results: Significant increases in 24-h urinary output, urinary sodium excretion, random urinary sodium/potassium ratio and significant reductions in body weight, abdominal girth, plasma renin activity and plasma aldosterone concentration (P < 0.05) were noted after 1 month in the halphabarol group. Furthermore, the effective diuretic doses and the need for large-volume paracentesis were significantly reduced in the halphabarol group compared to the SDT group after 1 month of therapy. No significant changes in the aforementioned parameters were noted in the SDT group. There were no significant changes in the scores of end-stage liver disease in both groups. Conclusions: These results suggest that the addition of halphabarol to SDT improves enhances water and sodium excretion, providing better control in cirrhotic ascitic patients resistant to SDT.
Authors and Affiliations
Dr. Ahmed M. Ali
Keywords
Related Articles
- EP ID EP628325
- DOI -
- Views 207
- Downloads 0
IXORA COCCINEA- A REVIEW
Ixora coccinea Linn., (Rubiaceae) commonly known as jungle of geranium and red ixora, is an evergreen shrub found throughout India. Depending on the medical condition, the flowers, leaves, roots, and the stem are used to...
PERIODONTITIS AND DIABETES ARE THEY INTER-RELATED??-A REVIEW ARTICLE
Diabetes mellitus (DM) is a metabolic disease that has become one of the most prevalent diseases in the world. In many of the patients, the diabetes remains undiagnosed.[1,2] More importantly, the prevalence of DM has tr...
AICARDI SYNDROME: CASE REPORT
Aicardi syndrome is a congenital disorder characterized by severe psychomotor retardation, corpus callosum agenesis, chorioretinal lacunae, and early-onset infantile spasms. The prognosis is generally poor for children w...
THE NEONATAL MORTALITY IN TERTIARY HOSPITAL (BAGHDAD TEACHING HOSPITAL): RISK FACTORS
Background: The neonatal period (first 28 days of life) is the most critical time for a child’s survival. Neonatal mortality risk factors are complex, relatively improved slowly, but remains a major concern in developing...
ANALYTICAL METHODOLOGIES FOR DETERMINATION OF ITRACONAZOLE AND TERBINAFINE HCL IN BULK AND PHARMACEUTICAL DOSAGE FORMS: AN OVERVIEW
Itraconazole is one of the triazole antifungal agent used in treatment of fungal infection. Itraconazole inhibits cytochrome P-450-dependent enzyme resulting in impairment of ergosterol synthesis. Terbinafine Hydrochlori...